

Epilepsy Drugs Market: Global Demand, Growth Potential & Opportunity Outlook 2021

https://marketpublishers.com/r/EDCF9CEB812EN.html

Date: March 2017

Pages: 80

Price: US\$ 800.00 (Single User License)

ID: EDCF9CEB812EN

Abstracts

Epilepsy Drugs Market is likely to reach nearly USD 5.5 Billion by the year end of 2021.

Market growth can be attributed to factors such as rising incidence of neurological disorders, growing disease awareness, introduction of novel antiepileptic drugs (AEDs), strong government support and initiatives. Moreover, increasing R&D investment and launch of extended-release formulations are further expected to fuel the market growth. However, high cost of patented drugs, concerns over decreasing healthcare costs as part of government austerity measures, particularly in Europe and low accessibility to antiepileptic drugs in low and middle income countries, are likely to restrict the market growth.

Vimpat is the undisputed leading drug of Global Epilepsy Drugs Market. It has a market share of nearly 22% in 2016 and is expected that Vimpat will gain its momentum till the forecasting period. Keppra was the second highest market share taker with more than 19% share in 2016 but the prospect of this drug will change due to the patent expiration in 2018 and its share decline to XX% by 2021. It is expected that Lamictal will be second leading drug with nearly XX% share by 2021. Onfi hold the third highest share of the Epilepsy Drugs market, being followed by Depakine by the year end of 2021.

The research report titled "Epilepsy Drugs Market: Global Demand, Growth Potential & Opportunity Outlook 2021" examines the market, competitive landscape and trends of the Global Epilepsy Drug Market. This report analyzes market data and provides a better understanding of Epilepsy Drugs sales value and demand in the Global Market. Market outlook in value terms for the forecasted period for Epilepsy Drugs Market has been detailed in the report. Key trends in terms of collaborations, partnerships and licensing agreements are analysed with details. The report also explores detailed



description of growth drivers and inhibitors of the Global Epilpesy Drugs Market.

The report concludes with the profiles of major players in the Epilepsy Drugs Market such as UCB, EISAI, Pfizer, Sanofi and Lundbeck. The major market players are evaluated on various parameters such as company overview and latest development and trends in the Epilepsy Drugs Market

Key Topics Covered in the Report

Worldwide Epilepsy Drugs Market Analysis (2013 – 2021)

Worldwide Epilepsy Drugs Market Share (2013 – 2021)

Worldwide Epilepsy Drugs Brand Market Performance (2013 – 2021)

Epilepsy Drugs Market – Major Deal Types

Key Companies Analysis

Key Drivers and Inhibitors of the Epilepsy Drugs Market

Key Epilepsy Drugs Covered in the Report are as follows:

- 1. Vimpat(Lacosamide)
- 2. Keppra(Levetiracetam)
- 3. Briviact(Brivaracetam)
- 4. Lamictal(Lamotrigine)
- 5. Neurontin (Gabapentin)
- 6. Depakine (Sodium Valproate)
- 7. Sabril (Vigabatrin)
- 8. Onfi(Clobazam)
- 9. Fycompa(Perampanel)
- 10. Inovelon/Banzel(Rufinamide)
- 11. Zonegran (Zonisamide)
- 12. Zebinix (Eslicarbazepine Acetate)

Key Companies Covered in the Report are as follows:



- 1. UCB
- 2. EISAI
- 3. Pfizer
- 4. Sanofi
- 5. Lundbeck



Contents

- 1. EXECUTIVE SUMMARY
- 2. WORLDWIDE EPILEPSY DRUGS MARKET ANALYSIS (2013 2021)
- 3. WORLDWIDE EPILEPSY DRUGS MARKET SHARE (2013 2021)
- 4. KEY DRIVERS AND INHIBITORS OF THE EPILEPSY DRUGS MARKET
- 4.1 Market Drivers
- 4.2 Inhibitors

5. WORLDWIDE – EPILEPSY DRUGS BRAND MARKET PERFORMANCE (2013 – 2021)

- 5.1 Vimpat(Lacosamide) UCB
- 5.2 Keppra(Levetiracetam) UCB
- 5.3 Briviact(Brivaracetam) UCB
- 5.4 Lamictal(Lamotrigine) GlaxoSmithKline
- 5.5 Neurontin (Gabapentin) Pfizer
- 5.6 Depakine (Sodium Valproate) Sanofi
- 5.7 Sabril (Vigabatrin) Lundbeck
- 5.8 Onfi(Clobazam) Lundbeck
- 5.9 Fycompa(Perampanel) EISAI
- 5.10 Inovelon/Banzel(Rufinamide) EISAI
- 5.11 Zonegran (Zonisamide) EISAI
- 5.12 Zebinix (Eslicarbazepine Acetate) EISAI

6. EPILEPSY DRUGS MARKET - MAJOR DEAL TYPES

- 6.1 Epilepsy Drugs Market Collaboration Deals
- 6.2 Epilepsy Drugs Market Licensing Agreement
- 6.3 Epilepsy Drugs Market Partnerships Deals

7. KEY COMPANIES ANALYSIS

7.1 UCB

7.1.1 Business Overview



- 7.1.2 Epilepsy Drugs Latest Development & Trends
- 7.1 EISAI
 - 7.1.1 Business Overview
 - 7.1.2 Epilepsy Drugs Latest Development & Trends
- 7.2 Pfizer
 - 7.2.1 Business Overview
 - 7.2.2 Epilepsy Drugs Latest Development & Trends
- 7.3 Sanofi
 - 7.3.1 Business Overview
 - 7.3.2 Epilepsy Drugs Latest Development & Trends
- 7.4 Lundbeck
 - 7.4.1 Business Overview
 - 7.4.2 Epilepsy Drugs Latest Development & Trends



List Of Figures

LIST OF FIGURES

- Figure 2–1: Worldwide Epilepsy Drugs Market (Million US\$),2013 2016
- Figure 2–2: Worldwide Forecast for Epilepsy Drugs Market (Million US\$),2017 2021
- Figure 5–1: Worldwide Vimpat Drug Sales (Million US\$), 2013 2016
- Figure 5–2: Worldwide Forecast for Vimpat Drug Sales (Million US\$), 2017 2021
- Figure 5–3: Worldwide Keppra Drug Sales (Million US\$), 2013 2016
- Figure 5-4: Worldwide Forecast for Keppra Drug Sales (Million US\$), 2017 2021
- Figure 5–5: Worldwide Briviact Drug Sales (Million US\$), 2016 2021
- Figure 5-6: Worldwide Lamictal Drug Sales (Million US\$), 2013 2016
- Figure 5–7: Worldwide Forecast for Lamictal Drug Sales (Million US\$), 2017 2021
- Figure 5-8: Worldwide Neurotin Drug Sales (Million US\$), 2013 2016
- Figure 5–9: Worldwide Forecast for Neurotin Drug Sales (Million US\$), 2017 2021
- Figure 5–10: Worldwide Depakine Drug Sales (Million US\$), 2013 2016
- Figure 5-11: Worldwide Forecast for Depakine Drug Sales (Million US\$), 2017 2021
- Figure 5–12: Worldwide Sabril Drug Sales (Million US\$), 2013 2016
- Figure 5–13: Worldwide Forecast for Sabril Drug Sales (Million US\$), 2017 2021
- Figure 5–14: Worldwide Onfi Drug Sales (Million US\$), 2013 2016
- Figure 5–15: Worldwide Forecast for Onfi Drug Sales (Million US\$), 2017 2021
- Figure 5–16: Worldwide Fycompa Drug Sales (Million US\$), 2013 2016
- Figure 5–17: Worldwide Forecast for Fycompa Drug Sales (Million US\$), 2017 2021
- Figure 5–18: Worldwide Inovelon/Banzel Drug Sales (Million US\$), 2013 2016
- Figure 5–19: Worldwide Forecast for Inovelon/Banzel Drug Sales (Million US\$), 2017 2021
- Figure 5–20: Worldwide Zonegran Drug Sales (Million US\$), 2013 2016
- Figure 5–21: Worldwide Forecast for Zonegran Drug Sales (Million US\$), 2017 2021
- Figure 5–22: Worldwide Zebinix Drug Sales (Million US\$), 2013 2016
- Figure 5-23: Worldwide Forecast for Zebinix Drug Sales (Million US\$), 2017 2021



List Of Tables

LIST OF TABLES

- Table 3 1: Worldwide Epilepsy Drugs Market Share(Percent), 2013 2016
- Table 3 2: Worldwide Forecast for Epilepsy Drugs Market Share(Percent),2017 2021
- Table 4 1: Epilepsy Branded Drugs Price List(US\$),2017
- Table 6 1: Collaboration Deals in Epilepsy Drug Market, 2008 2017
- Table 6 2: Licensing Agreement in Epilepsy Drug Market, 2008 2016
- Table 6 3: Partnerships Deals in Epilepsy Drug Market, 2008 2016



I would like to order

Product name: Epilepsy Drugs Market: Global Demand, Growth Potential & Opportunity Outlook 2021

Product link: https://marketpublishers.com/r/EDCF9CEB812EN.html

Price: US\$ 800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/EDCF9CEB812EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:		
Last name:		
Email:		
Company:		
Address:		
City:		
Zip code:		
Country:		
Tel:		
Fax:		
Your message:		
	**All fields are required	
	Custumer signature	

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970